LCP: Assay, Glycosylated Hemoglobin: FDA Product Code 510(k) Clearances, Predicate Lineage, and Recall History (1978 to 2024)

U.S. FDA CDRH three-letter product classification LCP in Hematology (21 CFR 864.7470) reconciled across 1978 to 2024.

Review 249 FDA 510(k) clearances, 37 recalled K-numbers, and 103 cumulative 1976 to 2026 CDRH recall notices for LCP: Assay, Glycosylated Hemoglobin on Predicate Ledger.

Reconciled U.S. FDA 510(k) and Recall Summary for LCP: Assay, Glycosylated Hemoglobin
Regulatory MetricVerified Value
Entity ClassificationFDA 3-Letter Product Code (LCP, Class 2)
Clinical Advisory SpecialtyHematology (Panel HE)
Cleared FDA 510(k) Submissions (1976 to 2026)249 clearances (68 California, 27.3%)
Cleared 510(k)s Linked to a Recall Notice37 K-numbers (14.86% of cleared cohort)
Cumulative Historical Recall Notices (1976 to 2026)103 notices (0 Class I, 100 Class II, 3 Class III)
Currently Open vs Historical Recall StatusCumulative 1976 to 2026 FDA archive total (103 notices); verify live open vs terminated status per notice in dossier
Implantable and Life-Sustaining Clearances0 implantable (0.0%) and 0 life-sustaining
Median FDA 510(k) Review Duration100 days (90th percentile: 289 days)

Cumulative recall counts span 1976 to 2026 across U.S. FDA CDRH and openFDA public archives and combine closed historical notices with any currently open field actions. Browse all device cohorts, 20 clinical specialties, Shared 510(k) Predicate Lineage Stage, or reconciliation methodology.

Meru AI Healthcare Data Engineering: Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI → · AI for Healthcare Practice · Healthcare Price & Patent-Cliff Crosswalk Guide.